NCT03446417View on ClinicalTrials.gov

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

January 17, 2022

Study Completion Date

November 15, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

ZN-e4

Oral dose, tablet, daily dosing

Trial Locations (7)

11733

Site 1, East Setauket

17325

Site 3, Gettysburg

28204

Site 6, Charlotte

48201

Site 5, Detroit

91010

Site 2, Duarte

Unknown

Site 8, Banja Luka

Site 7, Sarajevo

All Listed Sponsors
lead

Zeno Pharmaceuticals, Inc.

INDUSTRY

NCT03446417 - A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter